Alzheimer treatment granted fast track designation by the FDA
STOCKHOLM: BioArctic AB’s partner Eisai announced today that lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of early Alzheimer disease (AD), was...
FDA Approves initiation of IGC’s cannabinoid trial on Alzheimer’s patients
POTOMAC: India Globalization Capital announced that on July 30, 2020, the U.S. Food and Drug Administration (FDA) notified IGC that it has authorized the Company...
IQ-AI receives FDA clearance to market StoneChecker software
LONDON: Imaging Biometrics, IQ-AI’s Milwaukee based subsidiary, received notification that the FDA has cleared StoneChecker Software for marketing in the USA. David Smith, Chief Executive...